Novavax Transfers Nuvaxovid Rights to Sanofi

An announcement from Novavax ( (NVAX) ) is now available.

On November 3, 2025, the FDA approved the transfer of the marketing authorization for Novavax‘s COVID-19 vaccine, Nuvaxovid™, to Sanofi Pasteur Inc. This transfer, part of a collaboration and license agreement, triggered a $25 million milestone payment to Novavax, with the company expecting the payment in the first quarter of 2026. This move aligns with Novavax’s strategy to secure non-dilutive capital, having already secured $225 million in 2025. The transfer allows Sanofi to manage the commercial and regulatory activities for Nuvaxovid in the U.S., potentially enhancing its market reach.

The most recent analyst rating on (NVAX) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.

Spark’s Take on NVAX Stock

According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.

Novavax’s overall stock score reflects financial challenges and a lack of strong technical momentum, partially offset by a positive earnings call and undervaluation. The company’s strategic partnerships and cost reductions are promising, but financial instability remains a concern.

To see Spark’s full report on NVAX stock, click here.

More about Novavax

Novavax, Inc. is a biotechnology company that focuses on the development of vaccines to address some of the world’s most pressing health challenges. The company utilizes its scientific expertise in protein-based nanoparticles and its Matrix-M adjuvant technology platform to develop vaccines. Novavax’s growth strategy includes optimizing existing partnerships, expanding its portfolio in infectious diseases, and forming new collaborations.

Average Trading Volume: 6,002,031

Technical Sentiment Signal: Sell

Current Market Cap: $1.28B

For an in-depth examination of NVAX stock, go to TipRanks’ Overview page.